AR125119A1 - Actividad antiviral de inhibidores de vps34 - Google Patents
Actividad antiviral de inhibidores de vps34Info
- Publication number
- AR125119A1 AR125119A1 ARP210103256A ARP210103256A AR125119A1 AR 125119 A1 AR125119 A1 AR 125119A1 AR P210103256 A ARP210103256 A AR P210103256A AR P210103256 A ARP210103256 A AR P210103256A AR 125119 A1 AR125119 A1 AR 125119A1
- Authority
- AR
- Argentina
- Prior art keywords
- formula
- patient
- effective amount
- compound
- inhibiting
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4706—4-Aminoquinolines; 8-Aminoquinolines, e.g. chloroquine, primaquine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Virology (AREA)
- Molecular Biology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Un método para paliar o tratar una infección viral en un paciente que lo necesite, caracterizado porque comprende administrar al paciente una cantidad terapéuticamente eficaz de un compuesto representado por la fórmula (1). Un método para inhibir la transmisión de un virus, un método para inhibir el ingreso viral, un método para inhibir la replicación viral, un método para minimizar la expresión de proteínas virales, o un método para inhibir la liberación de virus, caracterizado porque comprende administrar una cantidad terapéuticamente eficaz de un compuesto de fórmula (1) o sal farmacéuticamente aceptable, estereoisómero, o tautómero del mismo, a un paciente que sufra de una infección viral, y/o poner en contacto una cantidad eficaz de un compuesto de fórmula (1) o sal farmacéuticamente aceptable, estereoisómero, o tautómero del mismo, con una célula infectada por virus, donde el compuesto de fórmula (1) está representado por: fórmula (1). Un método para tratar una infección por Coronaviridae en un paciente que lo necesite que comprende administrar al paciente una cantidad terapéuticamente eficaz de un compuesto representado por la fórmula (1).
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063118516P | 2020-11-25 | 2020-11-25 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR125119A1 true AR125119A1 (es) | 2023-06-14 |
Family
ID=80683866
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP210103256A AR125119A1 (es) | 2020-11-25 | 2021-11-25 | Actividad antiviral de inhibidores de vps34 |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US20220184054A1 (es) |
| EP (1) | EP4251156A1 (es) |
| JP (1) | JP2023553807A (es) |
| CN (1) | CN117241800A (es) |
| AR (1) | AR125119A1 (es) |
| CA (1) | CA3200038A1 (es) |
| TW (1) | TW202237132A (es) |
| WO (1) | WO2022115543A1 (es) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR112023009531A2 (pt) | 2020-11-18 | 2023-10-03 | Deciphera Pharmaceuticals Llc | Gcn2 e inibidores de perk quinase e métodos de uso dos mesmos |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN116589461A (zh) | 2017-08-23 | 2023-08-15 | 思普瑞特生物科学公司 | 氮杂吲哚基吡啶酮化合物和二氮杂吲哚基吡啶酮化合物 |
-
2021
- 2021-11-24 JP JP2023530995A patent/JP2023553807A/ja active Pending
- 2021-11-24 CA CA3200038A patent/CA3200038A1/en active Pending
- 2021-11-24 WO PCT/US2021/060740 patent/WO2022115543A1/en active Application Filing
- 2021-11-24 US US17/534,764 patent/US20220184054A1/en active Pending
- 2021-11-24 EP EP21865374.9A patent/EP4251156A1/en active Pending
- 2021-11-24 CN CN202180090850.3A patent/CN117241800A/zh active Pending
- 2021-11-25 AR ARP210103256A patent/AR125119A1/es unknown
- 2021-11-25 TW TW110143953A patent/TW202237132A/zh unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CN117241800A (zh) | 2023-12-15 |
| JP2023553807A (ja) | 2023-12-26 |
| US20220184054A1 (en) | 2022-06-16 |
| WO2022115543A1 (en) | 2022-06-02 |
| EP4251156A1 (en) | 2023-10-04 |
| CA3200038A1 (en) | 2022-06-02 |
| TW202237132A (zh) | 2022-10-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2022012714A (es) | Inhibidores de la replicacion de norovirus y coronavirus. | |
| ZA202307575B (en) | Methods and modified nucleosides for treating coronavirus infections | |
| CL2023001476A1 (es) | Nuevos agentes antivirales derivados de la espiropirrolidina | |
| JOP20220200A1 (ar) | مركبات عالية النشاط ضد covid-19 | |
| CO2020013600A2 (es) | Tratamiento de la hidradenitis supurativa mediante el uso de inhibidores de jak | |
| CO2023002852A2 (es) | Péptidos funcionalizados como agentes antivirales | |
| BRPI0518760A2 (pt) | sal de potÁssio do composto, e, composiÇço farmacÊutica | |
| AR125119A1 (es) | Actividad antiviral de inhibidores de vps34 | |
| ES2570401T3 (es) | Métodos de tratamiento usando dosis únicas de oritavancina | |
| AR119158A1 (es) | Tratamientos de angioedema hereditario | |
| AR125121A1 (es) | Actividad antiviral de inhibidores de vps34 | |
| DOP2023000060A (es) | Inhibidores de la línea-1 para tratar enfermedades antecedentes de la invención | |
| BR112022022599A2 (pt) | Métodos de tratamento de covid-19 usando bardoxolona metil ou análogos da mesma | |
| CL2022002699A1 (es) | Métodos para tratar la esclerosis múltiple recidivante utilizando un inhibidor de la tirosina cinasa de bruton. | |
| MX2022013722A (es) | Cisteamina para el tratamiento de infección por sars-cov-2. | |
| AR127533A1 (es) | INHIBIDORES DEL SARS-CoV-2 PARA EL TRATAMIENTO DE INFECCIONES POR CORONAVIRUS | |
| AR128257A1 (es) | Compuestos y composiciones para tratar afecciones relacionadas con la actividad de sting | |
| CL2022002317A1 (es) | Métodos para tratar esclerosis múltiple progresiva primaria usando un inhibidor de tirosina quinasa de bruton. | |
| AR125120A1 (es) | Actividad antiviral de inhibidores de vps34 | |
| CL2021003312A1 (es) | Composición que comprende pridopidina y un análogo de la misma para el tratamiento de la enfermedad de huntington y síntomas de la misma. | |
| BR112022019858A2 (pt) | Métodos de tratamento de esclerose sistêmica | |
| US20230355644A1 (en) | Active ingredients and drugs for the therapy of viral diseases, especially corona infections, especially covid-19 | |
| MA57933A1 (fr) | Composés hautement actifs contre la covid-19 | |
| AR127115A1 (es) | Compuestos heterotricíclicos como inhibidores del gen kras | |
| AR126501A1 (es) | Nuevos agentes antivirales derivados de espiropirrolidina |